Development
Boston Scientific Corporation
BSX
$102.83
$0.400.39%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 504.00M | 504.00M | 270.00M | 314.00M | 140.00M |
| Total Depreciation and Amortization | 313.00M | 300.00M | 298.00M | 285.00M | 294.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 197.00M | 70.00M | 104.00M | 114.00M | 39.00M |
| Change in Net Operating Assets | -57.00M | -176.00M | -14.00M | -523.00M | 334.00M |
| Cash from Operations | 957.00M | 698.00M | 658.00M | 190.00M | 807.00M |
| Capital Expenditure | -267.00M | -190.00M | -143.00M | -111.00M | -212.00M |
| Sale of Property, Plant, and Equipment | 0.00 | 1.00M | 0.00 | 3.00M | 2.00M |
| Cash Acquisitions | -793.00M | 0.00 | -643.00M | -375.00M | 0.00 |
| Divestitures | -- | -- | -- | -- | 5.00M |
| Other Investing Activities | 7.00M | -8.00M | -54.00M | -1.00M | 22.00M |
| Cash from Investing | -1.05B | -197.00M | -840.00M | -484.00M | -183.00M |
| Total Debt Issued | -- | -37.00M | 37.00M | -- | 0.00 |
| Total Debt Repaid | 0.00 | -4.00M | -- | -- | 0.00 |
| Issuance of Common Stock | 17.00M | 75.00M | 27.00M | 63.00M | 19.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00 | 0.00 | -14.00M | -14.00M | -13.00M |
| Other Financing Activities | -2.00M | -18.00M | -7.00M | -118.00M | -5.00M |
| Cash from Financing | 15.00M | 16.00M | 43.00M | -69.00M | 1.00M |
| Foreign Exchange rate Adjustments | 4.00M | -5.00M | -3.00M | -- | 3.00M |
| Miscellaneous Cash Flow Adjustments | -- | 1.00M | -1.00M | -- | 1.00M |
| Net Change in Cash | -77.00M | 513.00M | -143.00M | -363.00M | 629.00M |